Previously, Lee et al. suggested that an IL4-dominant environment in the MLN induced by oral administration of α-GalCer suppresses Th1-driven Crohn's disease but promotes Th2-driven ulcerative colitis (29). Here, IL4 is linked to ulcerative colitis.